Being diagnosed with idiopathic multicentric Castleman disease (iMCD) may come as a surprise for you or your loved one, and you may not know where to start. Patient Connect can help you begin your treatment journey.
Patient Connect is a service offered by EUSA Pharma to help people who have been prescribed SYLVANT. If your insurance doesn’t cover your medication, we might be able to help. Talk to one of our dedicated associates to see if you qualify for financial assistance.
Our support team can also set up reminders for your upcoming infusion appointments and a lot more. Visit the Patient Connect website to learn more.
Patient ConnectACCELERATE is a registry created and maintained by the University of Pennsylvania that collects medical data about people suffering from Castleman disease. The information is then shared with researchers and doctors, with the goal of improving treatments and treatment plans.
The Castleman Disease Collaborative Network (CDCN) is on a mission to help fight Castleman disease, and it can only be achieved with your help.
We hope you’ll consider signing up for the registry and becoming part of this initiative.
Learn More Enroll in ACCELERATECastleman Disease Collaborative Network (CDCN) is a global initiative dedicated to accelerating research and treatment for Castleman disease.
Global Genes was established to connect, empower, and inspire the rare disease community.
National Organization for Rare Disorders (NORD) is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.
RareConnect is a place where rare disease patients can connect with others globally.
At EUSA Pharma, we are continually dedicated to bringing awareness to iMCD. In 2020, we partnered with The Balancing Act to raise awareness of the disease.
We interviewed Frank, an iMCD survivor, and Dr. David Fajgenbaum, a leading expert and also a survivor of Castleman disease.
Watch the video to learn more.
The term idiopathic means that the underlying cause or origin of a disease is unknown.
Castleman disease (CD) is a rare condition in which cells of the lymph nodes and related tissues grow rapidly but are not cancerous. If left undiagnosed and untreated, it can lead to organ failure or other harmful conditions.
Unicentric Castleman disease (UCD): Affects only a single lymph node
Multicentric Castleman disease (MCD): Affects multiple lymph nodes
Idiopathic multicentric Castleman disease (iMCD) is a rare disorder in which the body overproduces various cytokines. Cytokines are powerful molecules that are normally secreted by the cells of the immune system in response to infectious or noninfectious agents.
If these overabundant cytokines are quickly released into the bloodstream, a cytokine storm can occur, with potentially severe or life-threatening effects. In the case of people with iMCD, the cytokine interleukin-6, or IL-6, may be responsible for the storm.
iMCD is linked to an elevation of cytokines, in particular, IL-6. The source of IL-6 overproduction in iMCD is unknown, and the abnormal signaling can lead to a cytokine storm, which can start to attack the immune system.
iMCD is not cancer; however, it can mimic the symptoms of many other diseases, including some malignancies (ie, cancer), and can be challenging to diagnose.
Siltuximab (SYLVANT®) is recommended by the National Comprehensive Cancer Network® (NCCN®) as a preferred treatment option for iMCD. Siltuximab continues to be the first-line therapy recommended by the Castleman Disease Collaborative Network (CDCN) guidelines.
SYLVANT is also the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of people with multicentric Castleman disease (MCD) who have tested negative for human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8).
SYLVANT is the preferred treatment for people with iMCD. It is administered via a 1-hour intravenous (IV) infusion, under the supervision of a healthcare professional at an infusion center.
SYLVANT works by blocking IL-6, a molecule found in overabundance in people with iMCD. SYLVANT has been shown to resolve the commonly observed symptoms of iMCD and to reduce lymph node size over time.
Any medication can be associated with side effects, and it can vary from person to person. Here are some of the most common side effects observed in people taking SYLVANT:
The efficacy of SYLVANT was tested in a randomized clinical trial—the gold standard of clinical studies.
To see if you qualify for financial assistance, visit eusapatientconnect.com to find out if you’re eligible for co-payment assistance.
The removal and examination of tissue, cells, or fluids from the body.
Powerful molecules that are normally secreted by the cells of the immune system in response to infectious or noninfectious agents.
An overreaction of the body’s immune system in which too many cytokines are released into the bloodstream very quickly, with potentially severe or life-threatening effects.
The underlying cause or origin of a disease is unknown.
Lymph nodes make immune cells that help the body fight infection.
A key signaling molecule that helps to regulate the body’s immune system.
A doctor who evaluates the changes caused by disease in tissues and body fluids and helps reach a diagnosis.
Administration of a drug solution into a vein.
SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT is safe and effective in children.
Do not take SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Medication Guide for a complete list of ingredients in SYLVANT.
Infections. SYLVANT may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT.
Infusion and allergic reactions. If you have an infusion or allergic reaction while receiving SYLVANT, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction, your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT:
rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.
These are not all the possible side effects of SYLVANT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see full Prescribing Information and Patient Information for additional Important Safety Information.
Please click “OK” to continue or “CANCEL” to return to SYLVANT.COM.
Please wait a moment.
The removal and examination of tissue, cells, or fluids from the body.
Powerful molecules that are normally secreted by the cells of the immune system in response to infectious or noninfectious agents.
An overreaction of the body’s immune system in which too many cytokines are released into the bloodstream very quickly, with potentially severe or life-threatening effects.
The underlying cause or origin of a disease is unknown.
Lymph nodes make immune cells that help the body fight infection.
A key signaling molecule that helps to regulate the body’s immune system.
A doctor who evaluates the changes caused by disease in tissues and body fluids and helps reach a diagnosis.
Administration of a drug solution into a vein.